Abstract
Aim Little data is available regarding the effectiveness of natural foods in treating chronic constipation. We aimed to identify whether prune ameliorates chronic constipation and can be used safely for a relatively long time.
Methods In this double-blind, randomized, placebo-controlled trial, 84 subjects with chronic constipation, presenting more than 6 months before and persisting for more than 3 months, were randomized to prune (n=42) or placebo (n=42) intake for 8 weeks. We assessed daily Bristol stool form scale (BSFS) scores and stool frequencies and administered the gastrointestinal symptom rating scale (GSRS) questionnaire, as primary outcomes for constipation improvement.
Results The prune group showed significantly decreased rates of hard stool (BSFS1 or 2) and increased rates of normal stool (BSFS 3 or 4) after 1 week, which were more evident after 7 weeks between the two groups. Prune significantly increased stool frequency immediately after 1 week. Furthermore, GSRS of hard stools, flatulence, and incomplete evacuation significantly improved after 4-8 weeks of prune intake, of which constipation and hard stools were significantly reduced compared to the placebo group. In contrast, prune intake did not cause diarrhea, loose stools, or urgent need for defecation during 8 weeks evaluated by GSRS score. We found no abnormal laboratory tests of liver function, renal function, inflammation, or urinalysis after prune intake.
Conclusions Daily prune intake ameliorates chronic constipation, improving quality of life, and causes few diarrhea-related symptoms or side effects. Our results emphasize a new, useful, and easy strategy for chronic constipation. (UMIN ID:000041384)
Competing Interest Statement
This study was funded in full by MIKI Corporation. MIKI Corporation has outsourced some of this research to Oneness Support Co., Ltd. on a fee-for-service basis. TKoyama and HY are employees of MIKI Corporation. NN has received research grants from MIKI Corporation for omics analysis of feces, but he is not involved in data collection and statistical analysis. NM has received a payment from Oneness Support Co., Ltd. for work about the research. No other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
UMIN000041384
Funding Statement
This study was funded by MIKI Corporation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Miura Clinic (approval number: R2001) and the Tokyo Medical University (approval number: T2021-0243) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding and conflicts of interest This study was funded in full by MIKI Corporation. MIKI Corporation has a food product containing prunes. MIKI Corporation has outsourced some of this research to Oneness Support Co., Ltd. on a fee-for-service basis. Initial data analyses were undertaken by Hitoe Ushirodani, who is an employee of Oneness Support Co., Ltd. TKoyama and HY are employees of MIKI Corporation. NN has received research grants from MIKI Corporation for omics analysis of feces, but he is not involved in data collection and statistical analysis. NM has received a payment from Oneness Support Co., Ltd. for work about the research.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
